Anti-Human IL-5 (Clone14611)

Purified Recombinant Human IL-5 (Accession # P05113)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human IL-5 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human IL-5 (at 1.25 ng/ml) is 0.01 - 0.03 µg/ml.

Clone 14611 recognizes an epitope on human IL-5. In direct ELISA, this antibody shows approximately 3% cross-reactivity with rmIL-5.

IL-5 is a 26 kD TH2 cytokine and a homodimeric glycoprotein that is part of the hematopoietic family. IL-5 stimulates B cell growth as well as increases Ig secretion. It is the main factor that promotes the terminal differentiation of eosinophil progenitors and enhances the effector capacity of mature eosinophils. IL-5 is a major regulator of eosinophil accumulation in tissues. In fact, in Hodgkin lymphoma, the characteristically observed eosinophilia is suspected to result from an increased production of IL-5. IL-5 may also be the cause of several allergic diseases including asthma, where it is thought that eosinophils have a significant role in the disease pathology. There are several mAbs currently in use that target IL-5 for the treatment of severe eosinophilic asthma.

1. Capron, M. et al. (1994) J Exp Med 179: 703
2. Graber, P. et al. (1993) Nature 363: 172
3. Inokuma, S. et al. (2005) Int Arch Allergy Immunol 1: 55